English (UK)
中文版Min Zhou
Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Hainan Haiyao Co. , Ltd
BD DirectorJames Zhou
A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development. We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.
Nanjing TransTherabio
DirectorDr. John Zhu
Duality Biologics is a China biotech company focusing on the discovery, development and commercialization of new modality biologics to provide solutions to unmet medical needs for grievous diseases in Great China area. Backed by proprietary new modality platform ensuring fast biological validation and development, Duality Biologics has been building a combined pipeline of First-in-class and Best-in-class. Currently, Duality seeks for licensing-in opportunities in broad disease areas especially oncology and autoimmune diseases
Duality Biologics
Founder and CEOchuhan zong
A mainland based family fund， heavily investing healthcare and biotechs
Wu Capital
associateFangyue Zou
Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Responsive Web Design powered by 